Literature DB >> 7351117

Disposition of 14C-guanabenz in patients with essential hypertension.

R H Meacham, M Emmett, A A Kyriakopoulos, S T Chiang, H W Ruelius, B R Walker, R G Narins, M Goldberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7351117     DOI： 10.1038/clpt.1980.7

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  5 in total

1.  In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system.

Authors:  S Chong; S A Dando; K M Soucek; R A Morrison
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

Review 2.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 3.  Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-09       Impact factor: 9.546

4.  Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic.

Authors:  Sharon W Way; Joseph R Podojil; Benjamin L Clayton; Anita Zaremba; Tassie L Collins; Rejani B Kunjamma; Andrew P Robinson; Pedro Brugarolas; Robert H Miller; Stephen D Miller; Brian Popko
Journal:  Nat Commun       Date:  2015-03-13       Impact factor: 14.919

Review 5.  Centrally acting antihypertensive agents: an update.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-05       Impact factor: 3.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.